Breast Cancer Research and Treatment

, Volume 10, Issue 2, pp 169–175 | Cite as

Stimulation of breast cancer cellsin vitro by the environmental estrogen enterolactone and the phytoestrogen equol

  • W. V. Welshons
  • C. S. Murphy
  • R. Koch
  • G. Calaf
  • V. C. Jordan
Reports

Summary

The phenolic lignans enterolactone and enterodiol appear periodically in women's urine, dependent upon synthesis from plant-derived lignans by the intestinal microflora. The phytoestrogen equol is also present in women's urine, and is also derived from a vegetarian diet. Antiestrogenic or antiproliferative actions of these compounds have been postulated and related to the observation that there is a reduced incidence of breast cancer associated with diet. We evaluated the estrogenic and antiestrogenic activity of these compounds using four sensitive assays in tissue culture, including the use of human breast cancer cell lines T47D and MCF-7. Unexpectedly, we found that enterolactone and enterodiol, as well as equol, are weak estrogens, and that enterolactone and equol could stimulate the growth of estrogen-dependent breast cancer cell lines. We suggest that these environmental agents can promote the growth of breast cancer, particularly hormone-dependent metastases that may be located near the gut or in the mesenteries or liver, where the concentration of these intestinally produced compounds would be highest. Treatment with an antiestrogen such as tamoxifen blocks the estrogenic activity of these compounds. In the absence of treatment with an antiestrogen such as tamoxifen, hormonal therapy to block steroidal estrogen synthesis in a patient with breast cancer could conceivably be circumvented by a vegeterian diet rich in the precursors to estrogenic compounds such as enterolactone and equol.

Key words

dietary estrogens enterodiol enterolactone equol estrogen-stimulated growth hormone-dependent breast cancer phytoestrogens 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stitch SR, Toumba JK, Groen MB, Funke CW, Leemhuis J, Vink J, Woods GF: Excretion, isolation, and structure of a new phenolic constituent of female urine. Nature 287: 738–740, 1980PubMedGoogle Scholar
  2. 2.
    Setchell KDR, Lawson AM, Mitchell FL, Adlercreutz H, Kirk DN, Axelson M: Lignans in man and in animal species. Nature 287: 740–742, 1980PubMedGoogle Scholar
  3. 3.
    Axelson M, Setchell KDR: Conjugation of lignans in human urine. Febs Lett 122: 49–53, 1980PubMedGoogle Scholar
  4. 4.
    Axelson M, Setchell KDR: The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds. Febs Lett 123: 337–342, 1981PubMedGoogle Scholar
  5. 5.
    Setchell KDR, Lawson AM, Borriello SP, Harkness R, Gordon H, Morgan DML, Kirk DN, Adlercreutz H, Anderson LC, Axelson M: Lignan formation in man-microbial involvement and possible roles in relation to cancer. Lancet 2: 4–7, 1981PubMedGoogle Scholar
  6. 6.
    Axelson M, Sjovall J, Gustafsson BE, Setchell KDR: Origins of lignans in mammals and identification of a precursor from plants. Nature 298: 659–660, 1982PubMedGoogle Scholar
  7. 7.
    Adlercreutz H, Fotsis T, Heikkinen R, Dwyer JT, Woods M, Goldin BR, Gorbach SL: Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 2: 1295–1299, 1982PubMedGoogle Scholar
  8. 8.
    Dehennin L, Reiffsteck A, Jondet M, Thibier M: Identification and quantitative estimation of a lignan in human and bovine semen. J Reprod Fert 66: 305–309, 1982Google Scholar
  9. 9.
    Cooley G, Farrant RD, Kirk DN, Patel S, Wynn S, Buckingham MJ, Hawakes GE, Hursthouse MB, Galas AMR, Lawson AM, Setchell KDR: Structural analysis of the urinary lignan 2,3-bis-(3-hydroxybenzyl)butan-4-olide (‘enterolactone’). A 400 MHz nuclear magnetic resonance study for the solution state and x-ray study for the crystal state. J Chem Soc Perkin Trans 2: 489–497, 1984Google Scholar
  10. 10.
    Borriello SP, Setchell KDR, Axelson M, Lawson AM: Production and metabolism of lignans by the human faecal flora. J App Bact 58: 37–43, 1985Google Scholar
  11. 11.
    Walters AP, Knowler JT: Effect of a lignan (HPMF) on RNA synthesis in the rat uterus. J Reprod Fert 66: 379–381, 1982Google Scholar
  12. 12.
    Hartwell JL: Types of anticancer agents isolated from plants. Cancer Treat Rep 60: 1031–1067, 1976PubMedGoogle Scholar
  13. 13.
    Barclay AS, Perdue Jr RE: Distribution of anticancer activity in higher plants. Cancer Treat Rep 60: 1081–1113, 1976PubMedGoogle Scholar
  14. 14.
    Axelson M, Kirk DN, Farrant RD, Cooley G, Lawson AM, Setchell KDR: The identification of the weak oestrogen equol [7-hydroxy-3-(4′-hydroxyphenyl)-chroman] in human urine. Biochem J 201: 353–357, 1982PubMedGoogle Scholar
  15. 15.
    Martin PM, Horwitz KB, Ryan DS, McGuire WL: Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103: 1860–1867, 1978PubMedGoogle Scholar
  16. 16.
    Labarca C, Paigen K: A simple, rapid and sensitive DNA assay procedure. Analyt Biochem 102: 344–352, 1980PubMedGoogle Scholar
  17. 17.
    Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J: Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4734–4740, 1983PubMedGoogle Scholar
  18. 18.
    Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4741–4745, 1983PubMedGoogle Scholar
  19. 19.
    Campen CA, Jordan VC, Gorski J: Opposing biological actions of antiestrogensin vitro andin vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology 116: 2327–2336, 1985PubMedGoogle Scholar
  20. 20.
    Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME: Structure-activity relationships of estrogens. Envir Health Perspec 61: 97–110, 1985Google Scholar
  21. 21.
    Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245–276, 1984PubMedGoogle Scholar
  22. 22.
    Chalbos D, Vignon F, Keydar I, Rochefort H: Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocr Metab 55: 276–283, 1982PubMedGoogle Scholar
  23. 23.
    Horwitz KB, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253: 2223–2228, 1978PubMedGoogle Scholar
  24. 24.
    Lippman ME, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976Google Scholar
  25. 25.
    Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Nat Acad Sci 83: 2496–2500, 1986PubMedGoogle Scholar
  26. 26.
    Braquet P, Senn N, Robin J-P, Esanu A, Godfraind T, Garay R: Inhibition of the erythrocyte Na+, K+-pump by mammalian lignans. Pharmacol Res Commun 18: 227–239, 1986PubMedGoogle Scholar
  27. 27.
    Fagoo M, Braquet P, Robin J-P, Esanu A, Godfraind T: Evidence that mammalian lignans show endogenous digitalis-like activity. Biochem Biophys Res Commun 134: 1064–1070, 1986PubMedGoogle Scholar
  28. 28.
    Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M: Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutrition 40: 569–578, 1984Google Scholar
  29. 29.
    Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984PubMedGoogle Scholar
  30. 30.
    Adlercreutz H, Fotsis T, Bannwart C, Wänälä K, Mäkelä T, Brunow G, Hase T: Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens in urine of women on various habitual diets. J Steroid Biochem 25: 791–797, 1986PubMedGoogle Scholar
  31. 31.
    Elkik F, Guyenne PN, Gompel A, Corvol P, Mercier-Bodard C, Mauvais-Jarvis P, Kuttenn F: Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol 143: 888–892, 1982PubMedGoogle Scholar
  32. 32.
    Holst J, Cajander S, Carlström K, Damber M-G, von Schoultz B: A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Brit J Obstet Gynaecol 90: 355–360, 1983Google Scholar
  33. 33.
    Miller AB: Role of nutrition in the etiology of breast cancer. Cancer 39: 2704–2708, 1977PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1987

Authors and Affiliations

  • W. V. Welshons
    • 1
  • C. S. Murphy
    • 1
  • R. Koch
    • 1
  • G. Calaf
    • 1
  • V. C. Jordan
    • 1
  1. 1.Department of Human OncologyUniversity of Wisconsin Clinical Cancer Center MadisonMadisonUSA

Personalised recommendations